Pregnancy as a window to the future: outcomes of antihypertensive therapy and superimposed preeclampsia in pregnant women with mild chronic hypertension (chap maternal follow-up study)
Active Project Grant Awarded Last action
- Award ID
- R01HL120338
- Recipient
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $26,344,761
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 94% complete
- Originally
- Funding
-
- $23,991,856.00 Federal
- $2,352,905.00 Non-federal
- Place of performance
- Irondale, AL 35210, USA
Award details come from USAspending.gov.
Description
- Abstract
- The large randomized multicenter chronic hypertension and pregnancy (CHAP) trial (2015-2021) was designed to evaluate the short-term benefits and safety of pharmacologic treatment of pregnant women with mild chronic hypertension (CHTN). This proposed CHAP maternal follow-up project (2021-2026) is a follow-up study of the well-characterized women in CHAP to address the critical knowledge gaps regarding whether future long-term cardiovascular disease (CVD) and other outcomes are associated with 1) antihypertensive therapy use early in pregnancy and 2) the development of superimposed preeclampsia (SI pre). CHTN is the most common major medical disorder seen in pregnancy, is most often mild (i.e. BP
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $2,007,149 | $0 | |
| Amendment | $1,976,808 | $0 | |
| Amendment | $2,046,886 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $2,103,237 | $0 | |
| Amendment | $2,103,237 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $2,262,182 | $0 | |
| Amendment | $2,262,182 | $0 | |
| Amendment | $2,262,182 | $0 | |
| Amendment | $2,262,182 | $0 | |
| Amendment | -$2,302,071 | $0 | |
| Amendment | -$2,302,071 | $0 | |
| Amendment | -$2,302,071 | $0 | |
| Amendment | -$2,302,071 | $0 | |
| Amendment | $2,302,071 | $0 | |
| Amendment | $2,302,071 | $0 | |
| Amendment | $2,302,071 | $0 | |
| Amendment | $2,302,071 | $0 | |
| Amendment | $2,352,905 | $0 | |
| Original award | $2,352,905 | $2,352,905 |
Show all 27
Subawards
Show 40 more
Latest 50 listed here. See the rest on GovTribe.
Quick answers
Who received award R01HL120338?
R01HL120338 was awarded to University Of Alabama At Birmingham by National Heart Lung and Blood Institute (National Institutes of Health) on September 1, 2014.
How much is award R01HL120338 worth?
$26,344,761 has been obligated on R01HL120338: $23,991,856 in federal funding and $2,352,905 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award